Spiperone hydrochloride (Spiroperidol hydrochloride) 是一种选择性的多巴胺D2受体 (D2,D3,D4,D1和 D5受体的Ki值分别为 0.06 nM,0.6 nM,0.08 nM,~350 nM,~3500 nM) 和5-HT2A/5-HT1A受体 (Ki为1 nM/49 nM) 拮抗剂。Spiperone hydrochloride 也是一种选择性的 α1B-肾上腺素受体 (α1B-adrenoceptor) 拮抗剂。Spiperone hydrochloride 激活钙激活的氯离子通道 (CaCC)。抗精神病和抗炎作用。
生物活性 | Spiperone hydrochloride (Spiroperidol hydrochloride) is a selectivedopamineD2receptor(Kivalues of 0.06 nM, 0.6 nM, 0.08 nM, ~350 nM, ~3500 nM forD2, D3, D4, D1and D5receptors, respectively) and5-HT2A/5-HT1Areceptor(Kis of 1 nM/49 nM) antagonist. Spiperone hydrochloride is also a selectiveα1B-adrenoceptorantagonist. Spiperone hydrochloride activatescalcium-activatedchloride channel(CaCC). Antipsychotic and anti-inflammatory activities[1][2][3][4][5]. |
IC50& Target[1][2][4] | D2Receptor 0.06 nM (Ki) | D1Receptor ~350 nM (Ki) | D3Receptor 0.6 nM (Ki) | D4Receptor 0.08 nM (Ki) | D5Receptor ~3500 nM (Ki) | 5-HT2AReceptor 1 nM (Ki) | 5-HT1AReceptor 49 nM (Ki) | α1B-adrenoceptor | Calcium-activated chloride channel |
|
体外研究 (In Vitro) | Spiperone is a potent intracellular Ca2+enhancer (EC50=9.3 μM) and stimulates intracellular Ca2+through a protein tyrosine kinase-coupled phospholipase C-dependent pathway, which results in increased secretion of Cl-in Calu-3 and CFBE41o-cell monolayers[2]. Spiperone significantly decreases the production of nitric oxide in lipopolysaccharide-stimulated BV-2 microglia cells, primary microglia and primary astrocyte cultures. Spiperone also significantly inhibits nitric oxide production in ATP-stimulated primary microglia cultures. Spiperone markedly decreases the production of TNF-α in BV-2 microglia cells. Spiperone attenuates the expression of inducible nitric oxide synthase and proinflammatory cytokines such as IL-1β and TNF-α at mRNA levels in BV-2 microglia cells[3].
|
体内研究 (In Vivo) | Spiperone (1.5 mg/kg; intraperitoneal injection; on days 1, 3, 6, 7, and 13-21; C57Bl/6 mice) treatment reduces infiltration of the alveolar interstitium and alveolar ducts with inflammatory cells and prevents the growth of the connective tissue in the parenchyma of Bleomycin lungs[6].
Animal Model: | C57Bl/6 mice (7-8-week-old) induced pulmonary fibrosis by Bleomycin[6] | Dosage: | 1.5 mg/kg | Administration: | Intraperitoneal injection; on days 1, 3, 6, 7, and 13-21 | Result: | Reduced infiltration of the alveolar interstitium and alveolar ducts with inflammatory cells and prevented the growth of the connective tissue in the parenchyma of bleomycin lungs. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
溶解性数据 | In Vitro: DMSO : 125 mg/mL(289.40 mM;Need ultrasonic) 配制储备液 1 mM | 2.3152 mL | 11.5759 mL | 23.1519 mL | 5 mM | 0.4630 mL | 2.3152 mL | 4.6304 mL | 10 mM | 0.2315 mL | 1.1576 mL | 2.3152 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (4.82 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (4.82 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (4.82 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (4.82 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.08 mg/mL (4.82 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (4.82 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|